Loading...

NAOV NANOVIBRONIX INC Disposals and divestitures 8-K Filing

NNVB

NV

NANOVIBRONIX INC

(NAOV)

2025 8-K

Name Change Announcement

Board Changes Announced

Shareholder Letter Issued

Securities Offering

Management Changes

Equity Offerings

Reverse Stock Split

Changes in Rights of Securi...

Equity Offerings

Promissory Note Issued

Director Resignation

Health Study Announcement

Stockholder Meeting

Merger Completion

Equity Issuance

Nasdaq Compliance

Annual Meeting Results

Stockholder Meeting

Contract Renewal

Nasdaq Delisting Notice

Nasdaq Delisting Notice

Annual Meeting Notice

Management Changes

Financial Update

Financial Update

Agreement with Veranex, Inc.

Cancellation of Special Mee...

Dismissal of Independent Re...

Departure of Directors or C...

Agreement Announcement

Nasdaq Compliance

Regulation FD Disclosure

Approval Announcement

Private Placement

Distribution Agreement Amen...

Delisting due to Non-Compli...

Distribution Agreement

Regulation FD Disclosure

Annual Meeting Announcement

Announcement of PainShield ...

Product Trial Results Annou...

Compliance Announcement

Reverse Stock Split

Regulation FD Disclosure

External Links:

On April 11, 2025, NanoVibronix's subsidiary ENvue Medical issued a $360,000 promissory note to Alpha Capital with an 8% interest rate, and the company guaranteed the note's obligations. Additionally, on April 9, 2025, the company confirmed compliance with Nasdaq's minimum bid price and stockholder equity requirements, but will be monitored for one year.

AI Assistant

NANOVIBRONIX INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.